This episode brings together much of what we have discussed so far regarding use of SLGT2 inhibitors. We’re joined for a case discussion by Professor Francesco Giorgino, who is Professor of Endocrinology at the University of Bari Aldo Moro in Italy, where he is also Chief of the Division of Endocrinology at the university hospital, and President of the Italian Society of Endocrinology.

For more free education, visit the DKIP website, follow us on Twitter (@dkipractice) or connect on LinkedIn. 

Disclosures:

Dr Professor Francesco Giorgino declares the following:

Grants/Research Support recipient: Eli Lilly, Roche Diabetes Care

Consultant (Occasional): Eli Lilly, Roche Diabetes Care, Boehringer Ingelheim, NovoNordisk, Sanofi

Honorarium recipient: Eli Lilly, Roche Diabetes Care, Boehringer Ingelheim, NovoNordisk, AstraZeneca, Sanofi, Mundipharma

All conflicts of interest have been mitigated prior to this activity.

Funding statement:

This independent educational activity is supported by educational grants from Eli Lilly, Merck Sharp and Dohme Corp. and Novo Nordisk A/S. The educational content has been developed by Liberum IME in conjunction with an independent steering committee; the financial supporters have had no influence on the content of this education.